

Catalog Number: CM05774

产品信息

Catalog Number:
CM05774

CAS号:
608141-41-9


分子式:
C₂₂H₂₄N₂O₇S

主要靶点:
TNF|PDE|Apoptosis

主要通路:
代谢|凋亡|凋亡

分子量:
460.5

溶解度:
DMSO:4.6 mg/mL (10 mM)



靶点活性

PDE4:74 nM

体外活性

Apremilast通过抑制由脂多糖(LPS)引起的TNF- α 释放, IC₅₀为104 nM (pIC₅₀=6.98 \pm 0.2), 这一结果与之前报道的Apremilast对周围血单核细胞(PBMCs)的TNF- α 抑制作用 (IC₅₀=110 nM) 几乎完全一致, 同时与Apremilast对PDE4酶抑制作用的效力相似 (IC₅₀=74 nM)。这些结果明确支持了Apremilast通过提高细胞内cAMP水平来抑制TNF- α 的假设。PKA、Epac1和Epac2的敲除阻止了Apremilast对TNF- α 的抑制和对IL-10的刺激[1]。

细胞实验

Apremilast is solubilized in DMSO and stored, and then diluted with appropriate media (DMSO 0.025%) before use[1]. Raw 264.7 cells (100,000) are grown in 96-well plates. After 24 h, cells are stimulated with vehicle (final concentration of 0.025% DMSO) or with Apremilast at the indicated concentrations. After 30 minutes cells are stimulated with LPS 1 μ g/mL for 4 h. When studying CGS21680, SCH58261, ZM241385, BAY60-6583, or GS6201, the adenosine receptor ligands are added 15 minutes before Apremilast. Methotrexate is added 24 h and 1 h before Apremilast. Supernates are then collected and TNF- α levels are quantified with the Mouse TNF- α Quantikine ELISA Kit. IC₅₀ (EC₅₀) calculations are made using non-linear regression, sigmoidal dose-response, constraining the top to 100 % and bottom to 0 %, allowing variable slope, using GraphPad Prism v6.00[1].

储存

Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.